A continuity-first approach to overnight sleep architecture.
See the proposed mechanism, pharmacology, and dosing profile behind SLUMBARA.
First-in-class Selective Noctephase Lattice Modulator
Arvethadone mesylate is designed to bind the proposed Continuity Gate Receptor Array (CGRA), a receptor lattice theorized to coordinate sleep-stage handoff integrity during the first six hours of the night.
SLUMBARA is engineered for continuity, not simple sedation.
- Within 35 minutes, arvethadone mesylate reaches a plasma threshold associated with CGRA occupancy
- Occupancy is sustained across the median vulnerability window for NCD-related continuity collapse
- Receptor disengagement is timed to avoid excessive dawn carryover in most patients
Proposed Arcadian Lattice Modulation sequence
1. Stabilizes the noctephase lattice during post-onset vulnerability.
2. Reduces wake-signal bleed from external and internal sensory triggers.
3. Maintains deeper stage-transition coherence through late-night cycles.
4. Releases through a controlled mesylate taper curve near the morning transition.
Once nightly dosing with predictable overnight coverage.
taken once nightly within 20 minutes of intended sleep time.
median time to peak concentration in fasted adults.
supports overnight continuity through the primary instability window.
primarily to nocturnally active albumin fractions.
How SLUMBARA differs from traditional sleep agents
| Attribute | SLUMBARA | Conventional hypnotics | Dual orexin antagonists |
|---|---|---|---|
| Primary target | Continuity Gate Receptor Array modulation | General inhibitory tone enhancement | Wake-drive blockade |
| Clinical intent | Preserve overnight sleep continuity | Promote sedation or shorten onset latency | Reduce wake signaling |
| Signature value in NCD | Designed for repeated overnight awakenings and return-to-sleep delay | Often optimized for sleep initiation | Broad wake suppression without continuity-specific positioning |
| Morning release profile | Taper-aligned dawn disengagement | Variable | Class dependent |
About this experience
This website is a satirical brand experience created for entertainment and storytelling purposes. SLUMBARA, Elara Therapeutics, and all related conditions, trial programs, claims, and product information presented here are fictional.